Table 1 Antiangiogenic Agents in Clinical trials

Bevacizumab (Avastin)

VEGF

Phase I, II, III

VEGF-Trap

VEGF

Recruiting

NM-3

VEGF

Recruiting

AE-941 (Neovastat)

VEGF, MMP

Phase I,II

IMC-1C11

VEGFR-2

Phase I

SU5416

VEGFR-2

Phase I, II

SU6668

VEGFR-2

Phase I

SU11248

VEGFR-1/2, PDGFR, KIT, FLT3

Phase I

PTK787/ZK222584

VEGFR-1/2

Phase I

ZD6474

VEGFR-2, EGFR

Recruiting

CP-547,632

VEGFR-2, FGFR-2, PDGFR

Recruiting

Endostatin

Various

Phase I

Angiostatin

Various

Phase I

TNP-470

Methionine aminopeptidase-2

Phase I

Thrombospondin-1 (ABT-510)

CD36

Recruiting

Vitaxin

Alphav/beta3

Phase I

EMD121974 (Cilengitide)

Alphav/beta3, alphav/beta5

Phase I

Combretastatin A4

Endothelial tubulin

Phase I

ZD6126

Endothelial tubulin

Recruiting

2-methoxyestradiol (2-ME)

microtubule

Recruiting

DMXAA

TNF-α induction

Phase I

Thalidomide

Various

Phase I, II, III

BMS-275291

MMP

Phase I

Celecoxib

COX-2

Phase I, II, III